%0 Journal Article %T A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting %A E. Susan Amirian %A Kathleen M. Aguilar %A Khalid Mezzi %A Marley Boyd %A Robert M. Rifkin %A Rohan Medhekar %A Sumeet Panjabi %A Thomas Wilson %J Archive of "Therapeutic Advances in Hematology". %D 2019 %R 10.1177/2040620718816699 %X Most multiple myeloma (MM) patients ultimately progress, with remission duration decreasing after first relapse. Recently, novel agents have been approved for the treatment of relapsed MM. There is a paucity of real-world data on these treatments. We sought to compare time to next treatment (TTNT) in MM patients in their second line of therapy (LOT2), treated with common proteasome inhibitor (PI)-based triplets %K carfilzomib %K comparative effectiveness %K multiple myeloma %K relapse %K second-line of therapy %U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348507/